Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$80.24 USD

80.24
1,245,584

+1.02 (1.29%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $80.25 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Hologic (HOLX) Divests Cynosure to Focus on Women's Health

Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.

Hologic (HOLX) Up 13.2% Since Last Earnings Report: Can It Continue?

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA

Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.

Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark

Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.

Hologic (HOLX) Set to Divest Medical Aesthetics Business

Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.

Hologic's (HOLX) 3DQuorum Imaging Technology Gets FDA Nod

The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.

Hologic's Aptima Genitalium Assay Gets Clinically Verified

This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.

Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates

Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.

Hologic (HOLX) Q4 Earnings Match Estimates

Hologic (HOLX) delivered earnings and revenue surprises of 0.00% and 2.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?

Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.

Urmimala Biswas headshot

Impressive Near-Term Outlook for Medical Instruments Industry

Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.

Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in Hologic (HOLX) Stock Now

Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View

Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.

Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

Solid growth in emerging markets is expected to be an added positive this earnings season.

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.

GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand

GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View

Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

Omnicell (OMCL) aims at product innovation through R&D.

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.

Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates

Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.

Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand

It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.

ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand

ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.

LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall

While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.